Serological Markers for Inflammatory Bowel Disease in AIDS Patients with Evidence of Microbial Translocation

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2010 Dec 3

PMID 21125014

Citations 15

Authors

Anupa Kamat

Petronela Ancuta

Richard S Blumberg

Dana Gabuzda

Affiliations

Soon will be listed here.

Abstract

Background: Breakdown of the gut mucosal barrier during chronic HIV infection allows translocation of bacterial products such as lipopolysaccharides (LPS) from the gut into the circulation. Microbial translocation also occurs in inflammatory bowel disease (IBD). IBD serological markers are useful in the diagnosis of IBD and to differentiate between Crohn's disease (CD) and ulcerative colitis (UC). Here, we evaluate detection of IBD serological markers in HIV-infected patients with advanced disease and their relationship to HIV disease markers.

Methods: IBD serological markers (ASCA, pANCA, anti-OmpC, and anti-CBir1) were measured by ELISA in plasma from AIDS patients (n = 26) with low CD4 counts (<300 cells/µl) and high plasma LPS levels, and results correlated with clinical data. For meta-analysis, relevant data were abstracted from 20 articles.

Results: IBD serological markers were detected in approximately 65% of AIDS patients with evidence of microbial translocation. An antibody pattern consistent with IBD was detected in 46%; of these, 75% had a CD-like pattern. Meta-analysis of data from 20 published studies on IBD serological markers in CD, UC, and non-IBD control subjects indicated that IBD serological markers are detected more frequently in AIDS patients than in non-IBD disease controls and healthy controls, but less frequently than in CD patients. There was no association between IBD serological markers and HIV disease markers (plasma viral load and CD4 counts) in the study cohort.

Conclusions: IBD serological markers may provide a non-invasive approach to monitor HIV-related inflammatory gut disease. Further studies to investigate their clinical significance in HIV-infected individuals are warranted.

Citing Articles

Different pattern of stool and plasma gastrointestinal damage biomarkers during primary and chronic HIV infection.

Pastor L, Langhorst J, Schroder D, Casellas A, Ruffer A, Carrillo J PLoS One. 2019; 14(6):e0218000.

PMID: 31185037 PMC: 6559643. DOI: 10.1371/journal.pone.0218000.

Systemic translocation of Staphylococcus drives autoantibody production in HIV disease.

Luo Z, Li M, Wu Y, Meng Z, Martin L, Zhang L Microbiome. 2019; 7(1):25.

PMID: 30764863 PMC: 6376754. DOI: 10.1186/s40168-019-0646-1.

The mycobiome in HIV.

Hager C, Ghannoum M Curr Opin HIV AIDS. 2017; 13(1):69-72.

PMID: 29028668 PMC: 5805152. DOI: 10.1097/COH.0000000000000432.

Probiotic supplementation promotes a reduction in T-cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ART-treated HIV-1-positive patients.

DEttorre G, Rossi G, Scagnolari C, Andreotti M, Giustini N, Serafino S Immun Inflamm Dis. 2017; 5(3):244-260.

PMID: 28474815 PMC: 5569369. DOI: 10.1002/iid3.160.

Raised Venous Lactate and Markers of Intestinal Translocation Are Associated With Mortality Among In-Patients With HIV-Associated TB in Rural South Africa.

Subbarao S, Wilkinson K, van Halsema C, Rao S, Boyles T, Utay N J Acquir Immune Defic Syndr. 2015; 70(4):406-13.

PMID: 26186506 PMC: 4625603. DOI: 10.1097/QAI.0000000000000763.

References

Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N . New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007; 56(10):1394-403. PMC: 2000264. DOI: 10.1136/gut.2006.108043. View

Koutroubakis I, Petinaki E, Mouzas I, Vlachonikolis I, Anagnostopoulou E, Castanas E . Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 2001; 96(2):449-54. DOI: 10.1111/j.1572-0241.2001.03524.x. View

Yoshida E, Chan N, HERRICK R, Amar J, Sestak P, Willoughby B . Human immunodeficiency virus infection, the acquired immunodeficiency syndrome, and inflammatory bowel disease. J Clin Gastroenterol. 1996; 23(1):24-8. DOI: 10.1097/00004836-199607000-00008. View

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

Caradonna L, Amati L, Lella P, Jirillo E, Caccavo D . Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease. Am J Gastroenterol. 2000; 95(6):1495-502. DOI: 10.1111/j.1572-0241.2000.02085.x. View

Dubinsky M . What is the role of serological markers in the diagnosis of IBD?. Inflamm Bowel Dis. 2008; 14 Suppl 2:S185-6. DOI: 10.1002/ibd.20585. View

Buckland M, Mylonaki M, Rampton D, Longhurst H . Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation. Clin Diagn Lab Immunol. 2005; 12(11):1328-30. PMC: 1287772. DOI: 10.1128/CDLI.12.11.1328-1330.2005. View

Seibold F . ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen?. Gut. 2005; 54(9):1212-3. PMC: 1774663. DOI: 10.1136/gut.2005.065227. View

Mow W, Vasiliauskas E, Lin Y, Fleshner P, Papadakis K, Taylor K . Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004; 126(2):414-24. DOI: 10.1053/j.gastro.2003.11.015. View

10.

Rutgeerts P, Vermeire S . Serological diagnosis of inflammatory bowel disease. Lancet. 2001; 356(9248):2117-8. DOI: 10.1016/s0140-6736(00)03488-7. View

11.

Papadakis K, Targan S . Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000; 51:289-98. DOI: 10.1146/annurev.med.51.1.289. View

12.

Macpherson A, Harris N . Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004; 4(6):478-85. DOI: 10.1038/nri1373. View

13.

Chase A, Zhou Y, Siliciano R . HIV-1-induced depletion of CD4+ T cells in the gut: mechanism and therapeutic implications. Trends Pharmacol Sci. 2005; 27(1):4-7. DOI: 10.1016/j.tips.2005.11.005. View

14.

Gardiner K, Halliday M, Barclay G, Milne L, Brown D, Stephens S . Significance of systemic endotoxaemia in inflammatory bowel disease. Gut. 1995; 36(6):897-901. PMC: 1382629. DOI: 10.1136/gut.36.6.897. View

15.

Bjarnason I, Sharpstone D, Francis N, Marker A, Taylor C, Barrett M . Intestinal inflammation, ileal structure and function in HIV. AIDS. 1996; 10(12):1385-91. DOI: 10.1097/00002030-199610000-00011. View

16.

Hunt P, Brenchley J, Sinclair E, McCune J, Roland M, Page-Shafer K . Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008; 197(1):126-33. PMC: 3466592. DOI: 10.1086/524143. View

17.

Austin G, Herfarth H, Sandler R . A critical evaluation of serologic markers for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5(5):545-7. DOI: 10.1016/j.cgh.2007.03.006. View

18.

Targan S . The utility of ANCA and ASCA in inflammatory bowel disease. Inflamm Bowel Dis. 1999; 5(1):61-3; discussion 66-7. DOI: 10.1097/00054725-199902000-00008. View

19.

Viazis N, Vlachogiannakos J, Georgiou O, Rodias M, Georgiadis D, Papastamopoulos V . Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. Inflamm Bowel Dis. 2009; 16(3):507-11. DOI: 10.1002/ibd.21077. View

20.

Linskens R, Mallant-Hent R, Groothuismink Z, Bakker-Jonges L, van de Merwe J, Hooijkaas H . Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur J Gastroenterol Hepatol. 2002; 14(9):1013-8. DOI: 10.1097/00042737-200209000-00013. View